SOFTWARE FOR OPTIMAL COMBINATION OF EXTERNAL BEAM RADIOTHERAPY (XRT) AND RADIOPHARMACEUTICAL THERAPY (RPT)
SOFTWARE FOR OPTIMAL COMBINATION OF EXTERNAL BEAM RADIOTHERAPY (XRT) AND RADIOPHARMACEUTICAL THERAPY (RPT)
批准号:
9578314
负责人:
Mickel Ghaly
金额:
$29.95万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-18 至 2018-06-17
关键词:
ClinicalClinical DataClinical ResearchClinical TrialsComputer softwareDataDevicesDocumentationDoseDose-RateExternal Beam Radiation TherapyFeedbackGoalsGrantInvestigationLabelLegal patentMalignant NeoplasmsManualsMapsMethodsPatientsPhasePreparationProcessRadiation therapyRadiopharmaceuticalsSamarium 153SystemTestingTimeToxic effectUnited States National Institutes of HealthValidationX-Ray Computed Tomographycommercializationdesigndosimetryosteosarcomaprospectivequantitative imagingsingle photon emission computed tomographytooltreatment planningtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
With 20+ years of NIH-R01 grant support the Frey and Sgouros labs have developed quantitative imaging and patented dosimetry methods that enable treatment planning of combination external beam radiotherapy (XRT) and radiopharmaceutical therapy (RPT). Combination XRT-RPT is orthogonal in terms of toxicity. RPT is especially suitable for disseminated cancer while providing a dose boost to tumors targeted by XRT. The overall workflow is to reconstruct and quantify the SPECT/CT images from RPT planning study, calculate dose-rate maps at each time point, integrate the dose-rate maps to create a dose map, using radiobiological principles convert the dose map to be consistent with XRT doses and combine this with a Sim-CT for import into an XRT dose planning system. The current implementation involves several discrete software packages and manual conversion steps and is tedious, error prone, and not suitable for clinical implementation or commercialization. The overall objective of this Phase I application is create a single streamlined, robust, integrated, and validated software package for combining RPT and XRT. We will: (1) Create develop the integrated software; (2) validate it using existing clinical data; and (3) prepare to submit an FDA IDE in preparation for the proposed
trial in Phase II.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
-
批准号:31070748
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2010
-
负责人:Christine Nardini
-
依托单位: